肿瘤坏死因子抑制与帕金森病:孟德尔随机化研究
本研究采用两样本孟德尔随机化方法,利用TNFRSF1A附近遗传变异作为TNF-TNFR1信号抑制的代理,评估长期TNF抑制对帕金森病风险及发病年龄的影响。结果显示TNF-TNFR1信号抑制未估计影响帕金森病风险(OR 0.99;95%CI 0.91-1.08)或发病年龄(晚0.13年;95%CI -0.66至0.92),但预测降低克罗恩病和溃疡性结肠炎风险、增加多发性硬化风险,提示TNF-TNFR1抑制不会预防或延迟帕金森病发病。
要点
- TNF-TNFR1信号抑制未估计影响帕金森病风险或发病年龄。
- 遗传代理验证显示对克罗恩病、溃疡性结肠炎和多发性硬化的预期效应。
- 证据等级为Class II,不支持TNF抑制用于预防或延迟帕金森病。
核心结论
- TNF-TNFR1信号抑制未估计影响帕金森病风险或发病年龄,不支持其预防或延迟帕金森病发病。
研究设计与样本
- 两样本孟德尔随机化研究,利用TNFRSF1A附近遗传变异作为TNF-TNFR1信号药理学阻断的代理。
- 基于全基因组关联研究汇总数据,循环C反应蛋白GWAS样本量204,402。
- 帕金森病风险分析纳入病例/对照37,688/981,372,发病年龄分析样本量28,568。
- 验证性分析评估遗传变异对克罗恩病、溃疡性结肠炎和多发性硬化风险的影响,样本量38,589-45,975。
主要发现
- TNF-TNFR1信号抑制未估计影响帕金森病风险(每降低10%循环CRP的OR=0.99;95%CI 0.91-1.08)。
- TNF-TNFR1信号抑制未估计影响帕金森病发病年龄(晚0.13年;95%CI -0.66至0.92)。
- 遗传索引的TNF-TNFR1信号阻断预测降低克罗恩病风险(OR 0.75;95%CI 0.65-0.86)和溃疡性结肠炎风险(OR 0.84;95%CI 0.74-0.97)。
- 遗传索引的TNF-TNFR1信号阻断预测增加多发性硬化风险(OR 1.57;95%CI 1.36-1.81)。
- 使用不同遗传工具和孟德尔随机化估计量的模型结果一致。
临床怎么用
- 神经科医生不应基于TNF-TNFR1抑制可预防或延迟帕金森病发病的假设使用抗TNF治疗。
- 对于接受抗TNF治疗的患者,无需因帕金森病风险考虑调整治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effects of long-term tumor necrosis factor (TNF) inhibition on the risk and age at onset of Parkinson disease (PD), we performed a 2-sample Mendelian randomization study using genome-wide association studies (GWAS) summary statistics. METHODS: Genetic variants in the vicinity of TNFRSF1A, the gene encoding TNF receptor 1 (TNFR1), were identified as predictive of pharmacologic blockade of TNFR1 signaling by anti-TNF therapy, based on genetic associations with lower circulating C-reactive protein (CRP; GWAS n = 204,402). The effects of TNF-TNFR1 inhibition were estimated for PD risk (ncases/controls = 37,688/981,372) and age at PD onset (n = 28,568) using GWAS data from the International Parkinson's Disease Genomics Consortium and 23andMe, Inc. To validate variants as proxies of long-term anti-TNF treatment, we also assessed whether variant associations reflected anticipated effects of TNFR1 inhibition on Crohn disease, ulcerative colitis, and multiple sclerosis risk (n = 38,589-45,975). RESULTS: TNF-TNFR1 signaling inhibition was not estimated to affect PD risk (odds ratio [OR] per 10% lower circulating CRP = 0.99; 95% confidence interval [CI] 0.91-1.08) or age at onset (0.13 years later onset; 95% CI -0.66 to 0.92). In contrast, genetically indexed TNF-TNFR1 signaling blockade predicted reduced risk of Crohn disease (OR 0.75; 95% CI 0.65-0.86) and ulcerative colitis (OR 0.84; 95% CI 0.74-0.97) and increased multiple sclerosis risk (OR 1.57; 95% CI 1.36-1.81). Findings were consistent across models using different genetic instruments and Mendelian randomization estimators. CONCLUSIONS: Our findings do not imply that TNF-TNFR1 signaling inhibition will prevent or delay PD onset. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that TNF-TNFR1 signaling inhibition is not associated with the risk or age at onset of PD.
引用
- Kang X, Ploner A, Pedersen NL, et al. Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study. Neurology. 2021. PMID: 33608417. doi:10.1212/WNL.0000000000011630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。